LT3347002T - Alzheimerio ligos gydymas tam tikroje pacientų populiacijoje - Google Patents

Alzheimerio ligos gydymas tam tikroje pacientų populiacijoje

Info

Publication number
LT3347002T
LT3347002T LTEPPCT/US2016/051091T LT16051091T LT3347002T LT 3347002 T LT3347002 T LT 3347002T LT 16051091 T LT16051091 T LT 16051091T LT 3347002 T LT3347002 T LT 3347002T
Authority
LT
Lithuania
Prior art keywords
alzheimer
disease
treatment
particular patient
patient population
Prior art date
Application number
LTEPPCT/US2016/051091T
Other languages
English (en)
Inventor
Susan ABUSHAKRA
Aidan POWER
Martin TOLAR
John Hey
Jeremy Yu
Petr Kocis
Original Assignee
Alzheon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3347002(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon, Inc. filed Critical Alzheon, Inc.
Publication of LT3347002T publication Critical patent/LT3347002T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/US2016/051091T 2015-09-10 2016-09-09 Alzheimerio ligos gydymas tam tikroje pacientų populiacijoje LT3347002T (lt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population

Publications (1)

Publication Number Publication Date
LT3347002T true LT3347002T (lt) 2023-09-11

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2016/051091T LT3347002T (lt) 2015-09-10 2016-09-09 Alzheimerio ligos gydymas tam tikroje pacientų populiacijoje

Country Status (21)

Country Link
US (3) US11191742B2 (lt)
EP (2) EP3347002B1 (lt)
JP (4) JP6789579B2 (lt)
KR (2) KR102547164B1 (lt)
CN (3) CN116712423A (lt)
AU (1) AU2016319107B2 (lt)
CA (1) CA2997376C (lt)
DK (1) DK3347002T3 (lt)
ES (1) ES2952727T3 (lt)
FI (1) FI3347002T3 (lt)
HR (1) HRP20230809T1 (lt)
HU (1) HUE062511T2 (lt)
LT (1) LT3347002T (lt)
MD (1) MD3347002T2 (lt)
MX (2) MX392677B (lt)
PL (1) PL3347002T3 (lt)
PT (1) PT3347002T (lt)
RS (1) RS64481B1 (lt)
SI (1) SI3347002T1 (lt)
SM (1) SMT202300250T1 (lt)
WO (1) WO2017044840A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143447A2 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
PT3347002T (pt) * 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes
CN114805211B (zh) 2017-03-21 2024-08-23 润佳（苏州）医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) * 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders
AU2019314323B2 (en) * 2018-08-01 2025-05-01 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
JP2022536803A (ja) * 2019-06-17 2022-08-18 アルツェオン・インコーポレーテッド 神経変性障害を治療する方法
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
IL313404A (en) * 2021-12-09 2024-08-01 Alzheon Inc ALZ-801 for use in the treatment of Alzheimer's disease
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1994009155A1 (en) 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
US20060257480A1 (en) * 2005-04-12 2006-11-16 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
BRPI0719379A2 (pt) 2006-11-24 2014-02-11 Ac Immune Sa Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
AU2011291506B2 (en) 2010-08-19 2016-07-28 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
LT2994160T (lt) * 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
RU2724190C2 (ru) 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
WO2015143447A2 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
PT3347002T (pt) * 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes

Also Published As

Publication number Publication date
CN108289870A (zh) 2018-07-17
EP3347002A4 (en) 2019-04-24
CA2997376C (en) 2024-05-14
WO2017044840A1 (en) 2017-03-16
HUE062511T2 (hu) 2023-11-28
CA2997376A1 (en) 2017-03-16
EP4275750B1 (en) 2026-05-06
CN116712423A (zh) 2023-09-08
MD3347002T2 (ro) 2023-10-31
AU2016319107A1 (en) 2018-03-22
MX2022003128A (es) 2022-08-02
US20220096406A1 (en) 2022-03-31
RS64481B1 (sr) 2023-09-29
KR102412997B1 (ko) 2022-06-23
EP4275750A2 (en) 2023-11-15
JP2020200352A (ja) 2020-12-17
KR102547164B1 (ko) 2023-06-22
JP2022145949A (ja) 2022-10-04
EP4275750A3 (en) 2024-01-17
ES2952727T3 (es) 2023-11-03
EP3347002A1 (en) 2018-07-18
EP3347002B1 (en) 2023-06-07
JP7128536B2 (ja) 2022-08-31
PL3347002T3 (pl) 2023-11-13
MX2018003023A (es) 2018-06-06
JP2025065545A (ja) 2025-04-17
DK3347002T3 (da) 2023-08-14
SMT202300250T1 (it) 2023-09-06
US11191742B2 (en) 2021-12-07
PT3347002T (pt) 2023-07-27
SI3347002T1 (sl) 2023-12-29
JP2018526407A (ja) 2018-09-13
AU2016319107B2 (en) 2021-02-25
JP6789579B2 (ja) 2020-11-25
HRP20230809T1 (hr) 2023-10-27
CN116712422A (zh) 2023-09-08
MX392677B (es) 2025-03-24
HK1257874A1 (en) 2019-11-01
KR20180051561A (ko) 2018-05-16
US20230414541A1 (en) 2023-12-28
FI3347002T3 (fi) 2023-08-10
KR20220042480A (ko) 2022-04-05

Similar Documents

Publication Publication Date Title
SMT202300250T1 (it) Trattamento della malattia di alzheimer in una particolare popolazione di pazienti
IL247085A0 (en) Methods for treating Alzheimer's disease
ZA201605341B (en) Methods of treating alzheimer's disease
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
IL263188B (en) Treatment for Parkinson's disease
PL3326637T3 (pl) Zastosowanie ekstraktu ze skórki mangostanu w preparatach leczniczych do leczenia chorób skóry
PT3458045T (pt) Ebselen para uso no tratamento da doença de ménière
PL3413870T3 (pl) Igmezyna do zastosowania do leczenia choroby alzheimera
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
PL3137093T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
IL263837A (en) Treatment of ocular disease
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
GB201511453D0 (en) Treatment of alzheimer's disease
AU2017902307A0 (en) Treatment of alzheimer's disease
AU2017902309A0 (en) Treatment of alzheimer's disease
GB201518052D0 (en) Parkinson's disease treatment
GB201504144D0 (en) Treatment of Parkinson's disease
GB201614863D0 (en) Alzheimer's disease
GB201610938D0 (en) Treatment of ocular disease